Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States

Neuro Oncol. 2023 Feb 14;25(2):424-429. doi: 10.1093/neuonc/noac270.

J Bryan Iorgulescu^{1

2}, Chuxuan Sun³, Corey Neff^{4

5}, Gino Cioffi^{4

6}, Catherine Gutierrez^{1

2}, Carol Kruchko⁴, Jennifer Ruhl⁷, Kristin Waite^{4

6}, Serban Negoita⁷, Jim Hofferkamp⁸, Tarik Tihan⁹, Roger McLendon^{10

11

12}, Daniel J Brat¹³, Quinn T Ostrom^{4

5

11

12}, Jill S Barnholtz-Sloan^{4

6

14}

¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School.
² Department of Medical Oncology, Dana-Farber Cancer Institute.
³ Department of Biostatistics, Duke University School of Medicine.
⁴ Central Brain Tumor Registry of the United States.
⁵ Department of Neurosurgery, Duke University School of Medicine.
⁶ Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.
⁷ Surveillance, Epidemiology, and End Results program, National Cancer Institute.
⁸ North American Association of Central Cancer Registries.
⁹ Division of Neuropathology, Department of Pathology, University of California San Francisco.
¹⁰ Department of Pathology, Duke University School of Medicine.
¹¹ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine.
¹² Duke Cancer Institute, Duke University Medical Center.
¹³ Department of Pathology, Northwestern University Feinberg School of Medicine.
¹⁴ Center for Biomedical Informatics & Information Technology, National Cancer Institute.

No abstract available

Publication types